S. Hernando Polo
YOU?
Author Swipe
View article: Alternative Splicing of Tcfl5 Fine-tunes Notch1 Transcriptional Output and Cell Fate Decisions in T-cell Acute Lymphoblastic Leukemias
Alternative Splicing of Tcfl5 Fine-tunes Notch1 Transcriptional Output and Cell Fate Decisions in T-cell Acute Lymphoblastic Leukemias Open
Aberrant NOTCH1 signaling drives T-cell acute lymphoblastic leukemia (T-ALL). TCFL5 is highly expressed in T-ALL clinical samples, producing four isoforms with distinct expression patterns and risk associations. In leukemic cells, TCFL5 is…
View article: 55P Long-term responders (LTR) with niraparib maintenance in platinum-sensitive recurrent high-grade serous ovarian cancer (PSROC) focusing on subsequent therapies and post-progression outcomes (GEICO-88R study)
55P Long-term responders (LTR) with niraparib maintenance in platinum-sensitive recurrent high-grade serous ovarian cancer (PSROC) focusing on subsequent therapies and post-progression outcomes (GEICO-88R study) Open
The GEICO-88R study evaluated the real-world use of niraparib (NIR) as maintenance treatment in patients (pts) with PSROC (Cueva et al, EJC 2023). A subanalysis of the LTR subgroup (NIR exposure ≥12 mo) was also communicated (Cueva et al, …
View article: Assessing a cut-off point for the diagnosis of abnormal uterine bleeding using the Menstrual Bleeding Questionnaire (MBQ): a validation and cultural translation study with Brazilian women
Assessing a cut-off point for the diagnosis of abnormal uterine bleeding using the Menstrual Bleeding Questionnaire (MBQ): a validation and cultural translation study with Brazilian women Open
The MBQ is a reliable questionnaire for Brazilian women. The cut-off ≥ 24 shows high accuracy to discriminate AUB.
View article: 36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial Open
The first-line setting represents the only opportunity for cure in advanced OC. 5-y PFS rates may predict cure as most pts not relapsing at 5 years are potentially cured. In the final overall survival (OS) analysis of the Phase III PAOLA-1…